Blueprint Medicines stock was soaring Monday after French drugmaker Sanofi said it had agreed to buy the biotech company for ...

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a ...

Blueprint Medicines came under pressure from Wall Street on Monday after at least six brokerages downgraded the stock ...

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib ...

With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...

Also Read: Blood Cancer-Focused Blueprint Medicines Could Be ‘Attractive Target For Partnerships’: Analyst Sanofi will pay $129.00 per share in cash, representing an equity value of ...

Late-stage results Otsuka presented in IgA nephropathy triggered a sell-off in Vera shares. Elsewhere, investors scrutinized ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.

Blueprint Medicines stock surges on news of a buyout by Sanofi. Skip to Main Content ... Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. By George Glover Share ...

Breakingviews provides financial professionals with unique agenda-setting insight on the major financial news stories as they ...